Active, not recruiting
Sponsor: Mirati Therapeutics Inc.
Collaborators:
Information provided by (Responsible party): Sponsor
ClinicalTrials.gov Identifier: NCT02219711
Type of dose limiting adverse event [Time Frame: Up to 3 weeks on treatment] [Designated as safety issue: ]
Area under the plasma concentration versus time curve (AUC) of MGCD516 [Time Frame: Up to 72 hours] [Designated as safety issue: ]
Peak Plasma Concentration (Cmax) of MGCD516 [Time Frame: Up to 72 hours] [Designated as safety issue: ]
Kind of metabolites of MGCD516 in blood plasma [Time Frame: Up to 9 weeks on treatment] [Designated as safety issue: ]
Concentration of selected marker proteins in blood plasma [Time Frame: Up to 9 weeks on treatment] [Designated as safety issue: ]
Percent of patients having objective disease response to treatment [Time Frame: Up to 1 year on treatment] [Designated as safety issue: ]
Ages Eligible for Study: N/A-N/A
Genders Eligible for Study: All
Accepts Healthly Volunteers: No
Mirati Therapeutics Inc.
No publications provided
MGCD516
MET
AXL
RET
TRK
NTRK
DDR2
KDR
VEGFR
PDGFRA
KIT
Tyrosine kinase inhibitor
NSCLC
Non-small cell lung cancer
Head and neck cancer
Renal cell carcinoma
Prostate cancer
Phase 1
CBL
Sitravatinib
Neoplasms
ClinicalTrials.gov processed this data on January 20, 2021